A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee - PubMed

Affiliations

• PMID: 20216203
• DOI: 10.1097/MJT.0b013e3181d169b5

Clinical Trial

A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee

J Zev Shainhouse et al. Am J Ther. 2010 Nov-Dec.

Abstract

To assess the long-term safety of a topical solution of diclofenac sodium in a vehicle containing dimethyl sulfoxide (TDiclo), subjects with radiologically confirmed, symptomatic osteoarthritis of the knee(s) applied the clinical dose of TDiclo (40 drops, four times daily) to each painful knee for up to 52 weeks. Safety assessment included adverse events, skin irritation scores of the treated knee(s), ocular examinations, and routine laboratory tests. There were 793 subjects (mean age, 62.5 years) who applied TDiclo to one or both (72%) knees for an average of 204 days, including 463 subjects for 6 months and 144 for 1 year. The most frequent adverse events were at the application site with no increase in incidence with prolonged exposure: dry skin (25.3%), contact dermatitis without vesicles (13.0%) or with vesicles (9.5%). Skin irritation score was 0 (normal) in 61.0% of subjects, 0.5 (dryness or flaking) in 23.9%, 1 or 2 (erythema without or with induration) in 6.9%, and 3 or 4 (erythema with induration and vesicles/bullae) in 8.2%. Subject dropouts included 114 (14.4%) with an application site skin adverse event. Individual subject laboratory test shift to abnormal occurred for hemoglobin (3.2%), aspartate aminotransferase (6.4%), alanine aminotransferase (7.3%), and creatinine (4.2%), but few shifts (less than 0.3% per variable) were clinically significant. No increased risk of cardiovascular or cataract events was noted. This long-term study of TDiclo revealed a safety profile comparable to that shown in multiple, shorter, well-controlled, double-blind trials with the predominant adverse effect noted being an application site reaction.

Similar articles

• Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis.

  Simon LS, Grierson LM, Naseer Z, Bookman AAM, Shainhouse ZJ. Simon LS, et al. Pain. 2009 Jun;143(3):238-245. doi: 10.1016/j.pain.2009.03.008. Epub 2009 Apr 19. Pain. 2009. PMID: 19380203 Clinical Trial.

• Topical therapy for osteoarthritis: clinical and pharmacologic perspectives.

  Altman R, Barkin RL. Altman R, et al. Postgrad Med. 2009 Mar;121(2):139-47. doi: 10.3810/pgm.2009.03.1986. Postgrad Med. 2009. PMID: 19332972 Review.

Cited by

• Skin Matters: A Review of Topical Treatments for Chronic Pain. Part Two: Treatments and Applications.

  Peppin JF, Albrecht PJ, Argoff C, Gustorff B, Pappagallo M, Rice FL, Wallace MS. Peppin JF, et al. Pain Ther. 2015 Jun;4(1):33-50. doi: 10.1007/s40122-015-0032-z. Epub 2015 Jan 29. Pain Ther. 2015. PMID: 25630651 Free PMC article.

• A Review of Topical Diclofenac Use in Musculoskeletal Disease.

  Nair B, Taylor-Gjevre R. Nair B, et al. Pharmaceuticals (Basel). 2010 Jun 11;3(6):1892-1908. doi: 10.3390/ph3061892. Pharmaceuticals (Basel). 2010. PMID: 27713334 Free PMC article. Review.

• The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.

  Yataba I, Otsuka N, Matsushita I, Matsumoto H, Hoshino Y. Yataba I, et al. Clin Drug Investig. 2016 Aug;36(8):673-82. doi: 10.1007/s40261-016-0412-0. Clin Drug Investig. 2016. PMID: 27229525 Free PMC article. Clinical Trial.

• Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches.

  Otterbach A, Lamprecht A. Otterbach A, et al. Pharmaceutics. 2021 Mar 1;13(3):320. doi: 10.3390/pharmaceutics13030320. Pharmaceutics. 2021. PMID: 33804395 Free PMC article.

• Topical NSAIDs for chronic musculoskeletal pain in adults.

  Derry S, Moore RA, Rabbie R. Derry S, et al. Cochrane Database Syst Rev. 2012 Sep 12;9(9):CD007400. doi: 10.1002/14651858.CD007400.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972108 Free PMC article. Updated. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database